Table 2.
Predicted Raltegravir, Elvitegravir, and Dolutegravir Resistance Among Patients With Integrase Genotypic Resistance Tests, 2009–2012a
| Predicted Resistance | No. (%) Among All Patients (n = 3012) | No. (%) Among Patients With Integrase Major Mutationb (n = 471) |
|---|---|---|
| Predicted raltegravir resistance | ||
| None (susceptible) | 2321 (77.1) | 0 (0) |
| Potential low-level | 183 (6.1) | 2 (0.4) |
| Low-level | 33 (1.1) | 2 (0.4) |
| Intermediate | 22 (0.7) | 14 (3.0) |
| High-level | 453 (15.0) | 453 (96.2) |
| Predicted elvitegravir resistance | ||
| None (susceptible) | 2332 (77.4) | 12 (2.6) |
| Potential low-level | 196 (6.5) | 18 (3.8) |
| Low-level | 63 (2.1) | 28 (5.9) |
| Intermediate | 20 (0.7) | 12 (2.6) |
| High-level | 401 (13.3) | 401 (85.1) |
| Predicted dolutegravir resistance | ||
| None (susceptible) | 2566 (85.2) | 57 (12.1) |
| Potential low-level | 199 (6.6) | 169 (35.9) |
| Low-level | 53 (1.8) | 51 (10.8) |
| Intermediate | 136 (4.5) | 136 (28.9) |
| High-level | 58 (1.9) | 58 (12.3) |
a Based on Stanford HIV Database interpretation, using 5 June 2013 update. All sequences analyzed on 7 June 2013.
b “Major” integrase mutations included: T66AIK, E92QV, F121Y, Y143CHR, S147G, Q148HKR, N155H.